(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it’s unclear how popular or effective it will…
Source:
Read full article at www.medpagetoday.com
Medical Disclaimer:
This content is for informational and educational purposes only.
It does not replace professional medical advice.






